Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) |
Texto Completo: | http://repositorio.ufes.br/handle/10/10951 |
Resumo: | Oral squamous cell carcinoma (OSCC) is the most common histological type of cancer of the oral cavity and presents a high mortality rate, about 50% of individuals diagnosed with OSCC evolve to death within a period of up to 5 years. Currently, there are no biomarkers able to predict prognosis and tumor progression features, in this way, the study of proteins responsible for apoptotic control and therefore involved in carcinogenesis has been in evidence. Thus, this study aims to evaluate the expression of Bcl-2 protein (B-cell lymphoma protein 2) as a prognostic biomarker and tumor progression in OSCC. We used clinical and follow-up data from 109 individuals with a conclusive diagnosis of OSCC. Histopathological analysis of gradation, patter of invasion, tumor lymphocytic infiltrate, perineural, vascular and lymphatic tumor invasion were evaluated on stained slides in Hematoxylin and Eosin. Fragments of tumor tissue, dysplasia and adjacent epithelium to the tumor were arranged in tissue microarrays and submitted to immunohistochemistry using anti-Bcl-2 antibody, clone 124. High Bcl-2 expression was observed in the tumor tissue, in relation to the adjacent epithelium to the tumor and dysplasia (p = 0.033), as well as on the tumor invasion front associated with the high degree of tumor lymphocytic infiltrate (p = 0.001). No difference was observed in Bcl-2 expression in tumor tissue when compared to clinical-pathological variables: tumor size, lymph node involvement, staging, age, gender, alcohol consumption and smoking. Additionally, Bcl-2 expression was not associated with prognosis in global and disease-free survival analyzes. We conclude that Bcl-2 protein may play an important role in indicating the malignant transformation potential of the oral epithelium in the tumor progression model used and may be a potential biomarker for the evolution of high-grade dysplasia for the CEO. However, in this study, Bcl-2 expression did not prove to be a good prognostic biomarker. |
id |
UFES_89d47098d88530b6d99ab43b00dfc4b7 |
---|---|
oai_identifier_str |
oai:repositorio.ufes.br:10/10951 |
network_acronym_str |
UFES |
network_name_str |
Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) |
repository_id_str |
2108 |
spelling |
Zeidler, Sandra Lúcia Ventorin vonhttps://orcid.org/0000-0002-8897-5747http://lattes.cnpq.br/5785612863130498Có, Anna Clara Gregoriohttps://orcid.org/0000-0002-7737-0371http://lattes.cnpq.br/3678557620411441Nogueira, Breno Valentimhttps://orcid.org/0000-0002-2199-0635http://lattes.cnpq.br/0011229320439147Pereira, Fausto Edmundo Limahttps://orcid.org/0000-0001-7471-8742http://lattes.cnpq.br/4065537941002091Silva, Tarcília Aparecida dahttps://orcid.org/0000-0001-9623-7835http://lattes.cnpq.br/50000326622803102019-03-19T02:00:40Z2019-03-182019-03-19T02:00:40Z2019-03-08Oral squamous cell carcinoma (OSCC) is the most common histological type of cancer of the oral cavity and presents a high mortality rate, about 50% of individuals diagnosed with OSCC evolve to death within a period of up to 5 years. Currently, there are no biomarkers able to predict prognosis and tumor progression features, in this way, the study of proteins responsible for apoptotic control and therefore involved in carcinogenesis has been in evidence. Thus, this study aims to evaluate the expression of Bcl-2 protein (B-cell lymphoma protein 2) as a prognostic biomarker and tumor progression in OSCC. We used clinical and follow-up data from 109 individuals with a conclusive diagnosis of OSCC. Histopathological analysis of gradation, patter of invasion, tumor lymphocytic infiltrate, perineural, vascular and lymphatic tumor invasion were evaluated on stained slides in Hematoxylin and Eosin. Fragments of tumor tissue, dysplasia and adjacent epithelium to the tumor were arranged in tissue microarrays and submitted to immunohistochemistry using anti-Bcl-2 antibody, clone 124. High Bcl-2 expression was observed in the tumor tissue, in relation to the adjacent epithelium to the tumor and dysplasia (p = 0.033), as well as on the tumor invasion front associated with the high degree of tumor lymphocytic infiltrate (p = 0.001). No difference was observed in Bcl-2 expression in tumor tissue when compared to clinical-pathological variables: tumor size, lymph node involvement, staging, age, gender, alcohol consumption and smoking. Additionally, Bcl-2 expression was not associated with prognosis in global and disease-free survival analyzes. We conclude that Bcl-2 protein may play an important role in indicating the malignant transformation potential of the oral epithelium in the tumor progression model used and may be a potential biomarker for the evolution of high-grade dysplasia for the CEO. However, in this study, Bcl-2 expression did not prove to be a good prognostic biomarker.O carcinoma epidermóide oral (CEO) é o tipo histológico mais comum do câncer da cavidade oral e apresenta elevada taxa de mortalidade, cerca de 50% dos indivíduos diagnosticados com CEO evoluem ao óbito dentro de um período de até 5 anos. Atualmente não existem biomarcadores capazes de predizer o prognóstico e a progressão tumoral, logo o estudo de proteínas responsáveis pelo controle apoptótico e, portanto, envolvidas na carcinogênese, tem estado em evidência. Assim, este estudo tem como objetivo avaliar a expressão da proteína Bcl-2 (B-cell lymphoma protein) como biomarcador de prognóstico e progressão tumoral em CEO. Utilizamos, para isso, dados clínicos e de seguimento de 109 indivíduos com diagnóstico conclusivo de CEO. Análise histopatológica de gradação, padrão de invasão, infiltrado linfocitário, invasão perineural, vascular e linfática tumoral foram avaliadas em lâminas coradas em Hematoxilina e Eosina. Fragmentos de tecido tumoral, displasia e epitélio adjacente ao tumor foram dispostos em microarranjos teciduais e submetidos à imuno-histoquímica, utilizando anticorpo anti-Bcl-2, clone 124. Elevada expressão de Bcl-2 foi observada no tecido tumoral, em relação ao epitélio adjacente ao tumor e displasia (p=0,033), bem como no fronte de invasão tumoral associado ao alto grau de infiltrado linfocitário tumoral (p=0,001). Não foi observada diferença entre a expressão de Bcl-2 em tecido tumoral quando comparada às variáveis clínico-patológicas: tamanho do tumor, comprometimento linfonodal, estadiamento, idade, sexo, consumo de álcool e tabaco. Adicionalmente, a expressão de Bcl-2 não foi associada ao prognóstico nas análises de sobrevida global e livre de doença. Concluímos que a proteína Bcl-2 pode ter papel importante em indicar o potencial de transformação maligna do epitélio oral no modelo de progressão tumoral utilizado, podendo ser um potencial biomarcador de evolução da displasia de alto grau para o CEO. No entanto, neste estudo, a expressão de Bcl-2 não mostrou ser um bom biomarcador de prognóstico.Texthttp://repositorio.ufes.br/handle/10/10951porUniversidade Federal do Espírito SantoMestrado em BiotecnologiaPrograma de Pós-Graduação em BiotecnologiaUFESBRCentro de Ciências da Saúdehttps://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessOral squamous cell carcinomaOral cavity cancer, BiomarkerBcl-2Carcinoma epidermóide oralCâncer da cavidade oralBiomarcadorB-cell lymphoma protein 2Biotecnologia61Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oralExpression of Bcl-2 protein as a potential biomarker of tumor progression in oral squamous cell carcinomainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisreponame:Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)instname:Universidade Federal do Espírito Santo (UFES)instacron:UFESannaclaragc@gmail.comORIGINAL13066_DissertacaoAnnaClaraGregorioCoversaofinalparaimpressao.pdfapplication/pdf5765962http://repositorio.ufes.br/bitstreams/6fa2597c-fefe-4a3a-96e4-bce5b7fac459/download7ed8e23c13272665a9a89697dc1c1bd8MD5110/109512024-07-24 16:58:21.457https://creativecommons.org/licenses/by-nc-nd/4.0/open accessoai:repositorio.ufes.br:10/10951http://repositorio.ufes.brRepositório InstitucionalPUBhttp://repositorio.ufes.br/oai/requestopendoar:21082024-10-15T17:52:40.696267Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) - Universidade Federal do Espírito Santo (UFES)false |
dc.title.none.fl_str_mv |
Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral |
dc.title.alternative.none.fl_str_mv |
Expression of Bcl-2 protein as a potential biomarker of tumor progression in oral squamous cell carcinoma |
title |
Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral |
spellingShingle |
Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral Có, Anna Clara Gregorio Oral squamous cell carcinoma Oral cavity cancer, Biomarker Bcl-2 Carcinoma epidermóide oral Câncer da cavidade oral Biomarcador B-cell lymphoma protein 2 Biotecnologia 61 |
title_short |
Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral |
title_full |
Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral |
title_fullStr |
Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral |
title_full_unstemmed |
Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral |
title_sort |
Expressão da proteína Bcl-2 como potencial biomarcador de progressão tumoral em carcinoma epidermóide oral |
author |
Có, Anna Clara Gregorio |
author_facet |
Có, Anna Clara Gregorio |
author_role |
author |
dc.contributor.authorID.none.fl_str_mv |
https://orcid.org/0000-0002-7737-0371 |
dc.contributor.authorLattes.none.fl_str_mv |
http://lattes.cnpq.br/3678557620411441 |
dc.contributor.advisor1.fl_str_mv |
Zeidler, Sandra Lúcia Ventorin von |
dc.contributor.advisor1ID.fl_str_mv |
https://orcid.org/0000-0002-8897-5747 |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/5785612863130498 |
dc.contributor.author.fl_str_mv |
Có, Anna Clara Gregorio |
dc.contributor.referee1.fl_str_mv |
Nogueira, Breno Valentim |
dc.contributor.referee1ID.fl_str_mv |
https://orcid.org/0000-0002-2199-0635 |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/0011229320439147 |
dc.contributor.referee2.fl_str_mv |
Pereira, Fausto Edmundo Lima |
dc.contributor.referee2ID.fl_str_mv |
https://orcid.org/0000-0001-7471-8742 |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/4065537941002091 |
dc.contributor.referee3.fl_str_mv |
Silva, Tarcília Aparecida da |
dc.contributor.referee3ID.fl_str_mv |
https://orcid.org/0000-0001-9623-7835 |
dc.contributor.referee3Lattes.fl_str_mv |
http://lattes.cnpq.br/5000032662280310 |
contributor_str_mv |
Zeidler, Sandra Lúcia Ventorin von Nogueira, Breno Valentim Pereira, Fausto Edmundo Lima Silva, Tarcília Aparecida da |
dc.subject.eng.fl_str_mv |
Oral squamous cell carcinoma Oral cavity cancer, Biomarker |
topic |
Oral squamous cell carcinoma Oral cavity cancer, Biomarker Bcl-2 Carcinoma epidermóide oral Câncer da cavidade oral Biomarcador B-cell lymphoma protein 2 Biotecnologia 61 |
dc.subject.por.fl_str_mv |
Bcl-2 Carcinoma epidermóide oral Câncer da cavidade oral Biomarcador B-cell lymphoma protein 2 |
dc.subject.cnpq.fl_str_mv |
Biotecnologia |
dc.subject.udc.none.fl_str_mv |
61 |
description |
Oral squamous cell carcinoma (OSCC) is the most common histological type of cancer of the oral cavity and presents a high mortality rate, about 50% of individuals diagnosed with OSCC evolve to death within a period of up to 5 years. Currently, there are no biomarkers able to predict prognosis and tumor progression features, in this way, the study of proteins responsible for apoptotic control and therefore involved in carcinogenesis has been in evidence. Thus, this study aims to evaluate the expression of Bcl-2 protein (B-cell lymphoma protein 2) as a prognostic biomarker and tumor progression in OSCC. We used clinical and follow-up data from 109 individuals with a conclusive diagnosis of OSCC. Histopathological analysis of gradation, patter of invasion, tumor lymphocytic infiltrate, perineural, vascular and lymphatic tumor invasion were evaluated on stained slides in Hematoxylin and Eosin. Fragments of tumor tissue, dysplasia and adjacent epithelium to the tumor were arranged in tissue microarrays and submitted to immunohistochemistry using anti-Bcl-2 antibody, clone 124. High Bcl-2 expression was observed in the tumor tissue, in relation to the adjacent epithelium to the tumor and dysplasia (p = 0.033), as well as on the tumor invasion front associated with the high degree of tumor lymphocytic infiltrate (p = 0.001). No difference was observed in Bcl-2 expression in tumor tissue when compared to clinical-pathological variables: tumor size, lymph node involvement, staging, age, gender, alcohol consumption and smoking. Additionally, Bcl-2 expression was not associated with prognosis in global and disease-free survival analyzes. We conclude that Bcl-2 protein may play an important role in indicating the malignant transformation potential of the oral epithelium in the tumor progression model used and may be a potential biomarker for the evolution of high-grade dysplasia for the CEO. However, in this study, Bcl-2 expression did not prove to be a good prognostic biomarker. |
publishDate |
2019 |
dc.date.accessioned.fl_str_mv |
2019-03-19T02:00:40Z |
dc.date.available.fl_str_mv |
2019-03-18 2019-03-19T02:00:40Z |
dc.date.issued.fl_str_mv |
2019-03-08 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufes.br/handle/10/10951 |
url |
http://repositorio.ufes.br/handle/10/10951 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
Text |
dc.publisher.none.fl_str_mv |
Universidade Federal do Espírito Santo Mestrado em Biotecnologia |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Biotecnologia |
dc.publisher.initials.fl_str_mv |
UFES |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Centro de Ciências da Saúde |
publisher.none.fl_str_mv |
Universidade Federal do Espírito Santo Mestrado em Biotecnologia |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) instname:Universidade Federal do Espírito Santo (UFES) instacron:UFES |
instname_str |
Universidade Federal do Espírito Santo (UFES) |
instacron_str |
UFES |
institution |
UFES |
reponame_str |
Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) |
collection |
Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) |
bitstream.url.fl_str_mv |
http://repositorio.ufes.br/bitstreams/6fa2597c-fefe-4a3a-96e4-bce5b7fac459/download |
bitstream.checksum.fl_str_mv |
7ed8e23c13272665a9a89697dc1c1bd8 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 |
repository.name.fl_str_mv |
Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) - Universidade Federal do Espírito Santo (UFES) |
repository.mail.fl_str_mv |
|
_version_ |
1813022509301235712 |